News

Published: March 2, 2026

OpenBind: delivering the UK’s AI for Science ambitions

The UK Government’s AI for Science Strategy and the UKRI AI Research and Innovation Strategic Framework set out an ambitious national agenda to accelerate discovery, strengthen global scientific leadership and translate AI‑enabled research into real‑world impact. The inclusion of OpenBind within these strategies reflects its role as a foundational capability helping to deliver this vision. 

A central priority across both frameworks is the creation of high‑quality, AI‑ready data as a shared national asset. Such datasets are recognised as critical enablers of AI‑driven breakthroughs, particularly in areas such as drug discovery and engineering biology. OpenBind directly addresses this need by generating large‑scale, open, FAIR protein–ligand structural datasets, designed to underpin the next generation of AI models for drug design and molecular discovery.

In doing so, OpenBind exemplifies the delivery model championed by UKRI: strong partnerships between research infrastructures, academia and industry, equitable access to national capabilities, and a clear pathway from research excellence to impact. By enabling AI‑designed therapeutics, improving reproducibility, and supporting end‑to‑end AI workflows, OpenBind contributes to shorter drug discovery timelines while reinforcing the UK’s reputation as a global leader in AI‑enabled life sciences. Seed funding from the Sovereign AI Unit further underscores confidence in this approach, highlighting how targeted investment in data, compute and infrastructure can translate national strategy into practical capability.

As OpenBind approaches the end of its first phase, the focus has been on establishing a robust proof of concept – developing the processes, protocols, and operational foundations needed to generate high‑quality, AI‑ready structural data at scale. This work has been supported by national assets highlighted in the AI for Science Strategy, including Isambard ‑ open AI supercomputer facilities in Bristol, used to train and validate models. Together, this first phase has laid the data, compute, and infrastructure foundations for future phases, positioning OpenBind to scale delivery and continue turning the UK’s AI for Science ambitions into sustained, long‑term capability.

Join our mailing list or follow us on our social media to keep up to date.

Related Announcements

August 21, 2026

Blog: OpenBind-0: Advancing Open Molecular Structure Prediction

Introducing OpenBind-0, a fully open molecular structure prediction model. This post presents the model, its performance, and new benchmark data that highlight both the promise and limitations of AI for drug discovery.

Our partners

Diamond logo
Columbia University logo
EBI logo
IPD logo
MedChemica logo
MSKCC logo
OMSF logo